US OptionsDetailed Quotes
AXSM250516P80000
- 0.51
- -0.01-1.92%
15min DelayClose Apr 30 16:00 ET
0.51High0.51Low
0.51Open0.52Pre Close1 Volume228 Open Interest80.00Strike Price51.00Turnover104.61%IV29.21%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier16DDays to Expiry0.51Extrinsic Value100Contract SizeAmericanOptions Type-0.0466Delta0.0040Gamma220.18Leverage Ratio-0.0733Theta-0.0023Rho-10.26Eff Leverage0.0227Vega
Axsome Therapeutics Stock Discussion
Axsome's MDD Drug Trial Reveals Unexpected Win in Sleepiness Subgroup
Axsome Wins 16+ Years of Market Exclusivity for Sunosi in Patent Settlement
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission
Can This New Migraine Drug Replace CGRP Inhibitors? Trial Shows 48x Success Rate
Axsome Shatters Expectations: Record 89% Growth for Depression Drug Auvelity, Pipeline Milestones Accelerate
Axsome Wins Major Victory: 15+ Years Market Protection for AUVELITY Secured in Patent Deal
has options
nfa be careful
1️⃣ Standard Designation: Standard designation is the typical pathway for drug development, involving preclinical studies and three phases of clinical trials to assess safety and efficacy thoroughly.
2️⃣ Orphan Designation: Reserved for drugs targeting rare diseases, this designation offers incentives like tax credits and marketing exclusivity to encourage development for underserved ...
No comment yet